Format

Send to

Choose Destination
Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Author information

1
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. nazhaa@ccf.org.
2
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
3
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
4
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
5
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6
Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA.
7
Groupe Francophone des mylodysplasies and Service Hematologie Senior, Hopital Saint Louis, Paris, France.
8
Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, USA.
9
Onconova Therapeutics, Inc., Newtown, PA, USA.
10
AOU Careggi, University of Florence, Florence, Italy.
11
Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
12
Universitätsklinikum Dresden, Dresden, Germany.
PMID:
29238044
PMCID:
PMC5802598
DOI:
10.1038/s41408-017-0018-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center